参考文献:
[1]WHO. Global health sector strategy on viral hepatitis 2016-2021[M/OL]. Geneva: World Health Organization, 2016. https://www.Who.int/hepatitis/strategy 2016-2021/ghss-hep/en/.
[2]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 Version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. (in Chinese)
中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J].临床肝胆病杂志, 2019, 35(12): 2670-2686.
[3]ALTHABE F, CHOMBA E, TSHEFU AK, et al. A multifaceted intervention to improve syphilis screening and treatment in pregnant women in Kinshasa, Democratic Republic of the Congo and in Lusaka, Zambia: A cluster randomised controlled trial[J]. Lancet Glob Health, 2019, 7(5): e655-e663.
[4]COWARD S, LEGGETT L, KAPLAN GG, et al. Cost-effectiveness of screening for hepatitis C virus: A systematic review of economic evaluations[J]. BMJ Open, 2016, 6(9): e011821.
[5]Prevalence of HIV and HCV infection in penitentiary institutions[EB/OL].http://www.institucionpenitenciaria.es/web/export/sites/default/datos/descargables/saludpublica/Prevalencia (2015).
[6]LLERENA S, COBO C, ALVAREZ S, et al. A program of testing and treat intended to eliminate hepatitis C in a prison: The JAILFREE-C study[J]. Hepatology, 2016, 64: 460A.
[7]DALGIC OO, SAMUR S, SPAULDING AC, et al. Improved health outcomes from hepatitis C treatment scale-up in Spain’s prisons: A cost-effectiveness study[J]. Sci Rep, 2019, 9(1): 16849.
[8]TASILLO A, EFTEKHARI YAZDI G, NOLEN S, et al. Short-term effects and long-term cost-effectiveness of universal hepatitis C testing in prenatal care[J]. Obstet Gynecol, 2019, 133(2): 289-300.
[9]ASSOUMOU SA, TASILLO A, LEFF JA, et al. Cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings[J]. Clin Infect Dis, 2018, 66(3): 376-384.
[10]HILL A, ANDREW B, MELISSA G, et al. Generic treatments for HIV, HBV, HCV, TB could be mass produced for <90 per patient[J]. J Int Aids Soc, 2017, 20: 44-45.
[11]HEATH K. Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C[J]. Clinicoecon Outcomes Res, 2018, 10: 539-550.
[12]CHAILLON A, MEHTA SR, HOENIGL M, et al. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection[J]. PLoS One, 2019, 14(6): e0217964.
[13]CIPRIANO LE, GOLDHABER-FIEBERT JD. Population health and cost-effectiveness implications of a “Treat All” recommendation for HCV: A review of the model-based evidence[J]. MDM Policy Pract, 2018, 3(1): 2381468318776634.
[14]KRAUTH C, ROSSOL S, ORTSTER G, et al. Elimination of hepatitis C virus in Germany: Modelling the cost-effectiveness of HCV screening strategies[J]. BMC Infect Dis, 2019, 19(1): 1019.
[15]WHO. Guidelines on hepatitis B and C testing[M]. Geneva: World Health Organization, 2017.
[16]HILL AM, NATH S, SIMMONS B. The road to elimination of hepatitis C: Analysis of cures versus new infections in 91 countries[J]. J Virus Erad, 2017, 3(3): 117-123.
[17]RINGELHAN M, MCKEATING JA, PROTZER U. Viral hepatitis and liver cancer[J]. Philos Trans R Soc Lond B Biol Sci, 2017, 372(1732): 20160274.
[18]SMITH BD, MORGAN RL, BECKETT GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965[J]. MMWR Recomm Rep, 2012, 61(RR-4): 1-32.
[19]SMITH BD, MORGAN RL, BECKETT GA, et al. Hepatitis C virus testing of persons born during 1945-1965: Recommendations from the centers for disease control and prevention[J]. Ann Intern Med, 2012, 157(11): 817-822.
[20]WARD JW. The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States[J]. Clin Liver Dis, 2013, 17(1): 1-11.
[21]MANJELIEVSKAIA J, BROWN D, SHRIVER CD, et al. CDC screening recommendation for baby boomers and hepatitis C virus testing in the US military health system[J]. Public Health Rep, 2017, 132(5): 579-584.
[22]WARD JW. The hidden epidemic of hepatitis C virus infection in the United States: Occult transmission and burden of disease[J]. Top Antivir Med, 2013, 21(1): 15-19.
[23]GREBELY J, BILODEAU M, FELD JJ, et al. The second Canadian symposium on hepatitis C virus: A call to action[J]. Can J Gastroenterol, 2013, 27(11): 627-632.
[24]GRAD R, THOMBS BD, TONELLI M, et al. Recommendations on hepatitis C screening for adults[J]. CMAJ, 2017, 189(16): e594-e604.
[25]TRUBNIKOV M, YAN P, NJIHIA J, et al. Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada (1991-2010): An age-period-cohort analysis[J]. Cmaj Open, 2014, 2(4): e281-e287.
[26]GOMAA A, ALLAM N, ELSHARKAWY A, et al. Hepatitis C infection in Egypt: Prevalence, impact and management strategies[J]. Hepat Med, 2017, 9: 17-25.
[27]RICHMOND JA, WALLACE J. Implementation of hepatitis C cure in Australia: One year on[J]. J Virus Erad, 2018, 4(2): 115-117.
[28]China National Narcotics Control Committee. Release of 2018 China Drug Situation Report: Overall better but still complex situation in drug control[J]. Shanghai Chem Industry, 2019, 44(7): 45. (in Chinese)
国家禁毒委员会. 2018年中国毒品形势报告发布:禁毒态势总体趋好、面临形势依然复杂[J]. 上海化工, 2019, 44(7): 45.
[29]ZHUANG H. Hepatitis C infection in China: Current status and measures for prevention and treatment[M]. Beijing: People’s Medical Publishing House, 2017. (in Chinese)
庄辉. 中国丙型肝炎感染现状及防治对策研究报告[M]. 北京: 人民卫生出版社, 2017.
[30]TAO LP, FU ZQ, LI ML, et al. Hepatitis C virus infection and related influencing factors in a drug rehabilitation center in Jiangsu Province, China[J]. Acta Univ Med Nanjing(Natural Sci), 2019, 39(10): 1464-1467, 1493. (in Chinese)
陶礼平, 符祖强, 李茂林, 等. 江苏省某戒毒所丙型肝炎病毒感染情况及影响因素分析[J]. 南京医科大学学报(自然科学版), 2019, 39(10): 1464-1467, 1493.
[31]CONG Y, WANG XG, YE L, et al. Analysis of sexually transmitted diseases infection and its influencing factors among isolated drug users in Zhejiang Province[J]. Chin J Health Lab Tec, 2020, 30(2): 252-254, 257. (in Chinese)
丛迎, 王晓光, 叶灵, 等. 浙江省强制隔离戒毒人群性传播疾病感染状况及影响因素分析[J]. 中国卫生检验杂志, 2020, 30(2): 252-254, 257.
[32]HU AY, DENG JH, DONG XY, et al. HIV and HCV infection status and influence factors among drug addicts under compulsory rehabilitation in Baoshan city of Yunnan province[J]. Chin J AIDS STD, 2019, 25(11): 1113-1116. (in Chinese)
胡安艳, 邓家欢, 董贤雅, 等. 保山市强制戒毒人员HIV和HCV感染状况及影响因素[J]. 中国艾滋病性病, 2019, 25(11): 1113-1116.
[33]van de VEN N, FORTUNAK J, SIMMONS B, et al. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus[J]. Hepatology, 2015, 61(4): 1174-1182.
[34]National Health and Family Planning Commission of the People’s Republic of China. Screening and management of viral hepatitis C [J]. Infect Dis Info, 2015, 1: 1-2. (in Chinese)
中华人民共和国国家卫生和计划生育委员会.丙型病毒性肝炎筛查及管理[J]. 传染病信息, 2015, 1: 1-2.
[35] CUI MJ. A case-control study of risk factors for HCV infection [D]. Beijing: Chinese Center for Disease Control and Prevention, 2014. (in Chinese)
崔妹娟. HCV感染危险因素的病例对照研究[D]. 北京: 中国疾病预防控制中心, 2014.
[36]National Health and Family Planning Commission, National Development and Reform Commission, Ministry of Education, et al. Action plan for the prevention and treatment of viral hepatitis in China(2017-2020) [J]. Chin J Viral Dis, 2018, 8(1): 1-5. (in Chinese)
国家卫生计生委, 国家发展改革委, 教育部, 等. 中国病毒性肝炎防治规划(2017-2020年)[J]. 中国病毒病杂志, 2018, 8(1): 1-5.
[37]LIU L, XU H, HU Y, et al. Hepatitis C screening in hospitals: Find the missing patients[J]. Virol J, 2019, 16(1): 47.
[38]LI R. Construction plan for national production bases of genuine medicinal materials (2018-2025) jointly issued by Ministry of Agriculture and Rural Affairs, National Medical Products Administration, and State Administration of Traditional Chinese Medicine[J]. J Tradit Chin Med Manage, 2018, 26(24): inside back cover. (in Chinese)
李芮. 三部委联合印发《全国道地药材生产基地建设规划(2018-2025年)》[J]. 中医药管理杂志, 2018, 26(24): 封3.
[39]Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study[J]. Lancet Gastroenterol Hepatol, 2017, 2(3): 161-176.
[40]TANG Y, SUN Q, GU CH, et al. Sentinel surveillance of HIV, hepatitis C and syphilis infections[J]. J Diagn Concepts Pract, 2013, 12(3): 352-354. (in Chinese)
汤琰, 孙乔, 顾春华, 等. 哨点监测人群中人类免疫缺陷病毒、梅毒、HCV感染的检测结果分析[J]. 诊断学理论与实践, 2013, 12(3): 352-354.
[41]Chinese Center for Disease Control and Prevention. Ministry of Health issued the epidemic situation of notifiable infectious diseases in 2008 and January 2009 in China[R/OL]. [2009-02-10] http://www.nhc. gov.cn/jkj/s3578/201304/c9244b1ae3ad48faa
8181b87b8caffd5.shtml. (in Chinese)
中国疾病预防控制中心.卫生部公布2009年1月及2008年度全国法定报告传染病疫情[R/OL]. [2009-02-10] http://www.nhc.gov.cn/jkj/s3578/201304/c9244b1ae3ad48faa818
1b87b8caffd5.shtml.
[42]Chinese Center for Disease Control and Prevention.An overview of the epidemic situation of notifiable infectious diseases in China, 2018[R/OL]. [2019-04-24] http://www.nhc.gov.cn/jkj/s3578/201904/050427ff32704a5db64f4ae1f6d57c6c.
shtml. (in Chinese)
中国疾病预防控制中心. 2018年全国法定传染病疫情概况[R/OL]. [2019-04-24]. http://www.nhc.gov.cn/jkj/s3578/201904/050427ff32704a5db64f4ae1f6d57c6c.shtml.